This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://linked.opendata.cz/resource/drugbank/drug/DB06718/identifier/pharmgkb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB06718/identifier/kegg-compound/
n6http://linked.opendata.cz/resource/drugbank/drug/DB06718/identifier/pubchem-compound/
n7http://linked.opendata.cz/resource/drugbank/drug/DB06718/identifier/pubchem-substance/
n10http://linked.opendata.cz/resource/drugbank/drug/DB06718/identifier/drugbank/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB06718/identifier/wikipedia/
n17http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06718
rdf:type
n3:Drug
n3:description
Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema. Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes.
n3:generalReferences
# Guilarte M, Luengo O, Nogueiras C, Labrador-Horrillo M, Munoz E, Lopez A, Cardona V: Acquired angioedema associated with hereditary angioedema due to C1 inhibitor deficiency. J Investig Allergol Clin Immunol. 2008;18(2):126-30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18447143 # Thevis M, Schanzer W: Synthetic anabolic agents: steroids and nonsteroidal selective androgen receptor modulators. Handb Exp Pharmacol. 2010;(195):99-126. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20020362 # Sloane DE, Lee CW, Sheffer AL: Hereditary angioedema: Safety of long-term stanozolol therapy. J Allergy Clin Immunol. 2007 Sep;120(3):654-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17765757
n3:group
approved
n3:halfLife
24 hours
n3:indication
Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating C1-inhibitor deficient hereditary angioedema. C1-inhibitor is a protease that inhibits the complement system (part of the innate immune system), a biochemical chain of reactions which assists the body in removing pathogens from the body. Stanozolol may help control attacks of hereditary angioedema. Stanozolol can be administered orally or intramuscularly.
owl:sameAs
n9:DB06718 n13:DB06718
dcterms:title
Stanozolol
adms:identifier
n6:5277 n7:99443270 n10:DB06718 n11:C07311 n14:PA165958391 n15:Stanozolol
n3:mechanismOfAction
Stanozolol binds to androgen receptors, such as membrane bound receptor proteins LAGS and stanozolol-binding protein (STBP).
n3:IUPAC-Name
n4:271B5137-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B513D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B513C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5139-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B513A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B513B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5135-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5133-363D-11E5-9242-09173F13E4C5 n4:271B5136-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5134-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n17:A14AA02
n3:H-Bond-Acceptor-Count
n4:271B5143-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5144-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B513E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B513F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5141-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5140-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5142-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
10418-03-8
n3:category
n3:Bioavailability
n4:271B5149-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B514B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B514C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5148-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5147-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B514A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5138-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5145-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5146-363D-11E5-9242-09173F13E4C5